106 related articles for article (PubMed ID: 26187221)
1. [The role of positron emission tomography in in lymphoma diagnosis and treatment].
Papamichael DC; Pianou NK; Chatzipavlidou V
Hell J Nucl Med; 2015; 18(2):173-9. PubMed ID: 26187221
[TBL] [Abstract][Full Text] [Related]
2. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
3. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
Chavdarova LI; Tzonevska AD; Piperkova EN
Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
[TBL] [Abstract][Full Text] [Related]
4. PET/CT, MR, and PET/MR in Lymphoma and Melanoma.
Schwenzer NF; Pfannenberg AC
Semin Nucl Med; 2015 Jul; 45(4):322-31. PubMed ID: 26050659
[TBL] [Abstract][Full Text] [Related]
5. FDG PET-CT in the management of primary breast lymphoma.
Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
[TBL] [Abstract][Full Text] [Related]
6. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
7. Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.
Cohen JB; Hall NC; Ruppert AS; Jones JA; Porcu P; Baiocchi R; Christian BA; Penza S; Benson DM; Flynn J; Andritsos LA; Devine SM; Blum KA
Bone Marrow Transplant; 2013 Sep; 48(9):1212-7. PubMed ID: 23584442
[TBL] [Abstract][Full Text] [Related]
8. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
Hagtvedt T; Seierstad T; Lund KV; Løndalen AM; Bogsrud TV; Smith HJ; Geier OM; Holte H; Aaløkken TM
Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas.
Stéphane V; Samuel B; Vincent D; Joelle G; Remy P; Francois GG; Jean-Pierre T
Eur J Radiol; 2013 Nov; 82(11):2011-7. PubMed ID: 23932096
[TBL] [Abstract][Full Text] [Related]
10. PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer.
Ceci F; Castellucci P; Graziani T; Schiavina R; Fanti S
PET Clin; 2015 Oct; 10(4):487-94. PubMed ID: 26384595
[TBL] [Abstract][Full Text] [Related]
11. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
12. Role of functional imaging in the management of lymphoma.
Cheson BD
J Clin Oncol; 2011 May; 29(14):1844-54. PubMed ID: 21482982
[TBL] [Abstract][Full Text] [Related]
13. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
[TBL] [Abstract][Full Text] [Related]
15. Imaging of multiple myeloma: usefulness of MRI and PET/CT.
Koppula B; Kaptuch J; Hanrahan CJ
Semin Ultrasound CT MR; 2013 Dec; 34(6):566-77. PubMed ID: 24332208
[TBL] [Abstract][Full Text] [Related]
16. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
17. Impact of FDG-PET/CT in the management of lymphoma.
Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
[TBL] [Abstract][Full Text] [Related]
18. Comparison of positron emission tomography/CT and bremsstrahlung imaging following Y-90 radiation synovectomy.
Barber TW; Yap KS; Cherk MH; Powell A; Kalff V
J Med Imaging Radiat Oncol; 2013 Oct; 57(5):567-71. PubMed ID: 24119270
[TBL] [Abstract][Full Text] [Related]
19. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
20. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review.
Treglia G; Annunziata S; Sobic-Saranovic D; Bertagna F; Caldarella C; Giovanella L
Acad Radiol; 2014 May; 21(5):675-84. PubMed ID: 24703482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
